Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1997 1
2001 1
2002 1
2003 2
2004 1
2005 2
2006 1
2007 1
2008 1
2009 1
2010 1
2011 2
2012 1
2013 3
2015 3
2016 5
2017 7
2018 7
2019 11
2020 8
2021 9
2022 14
2023 14
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Reiter A, George TI, Gotlib J. Reiter A, et al. Blood. 2020 Apr 16;135(16):1365-1376. doi: 10.1182/blood.2019000932. Blood. 2020. PMID: 32106312 Free article. Review.
Multilineage KIT involvement and multimutated clones are characteristic of advanced SM (advSM), especially SM with an associated hematologic neoplasm (AHN). A major challenge is how to integrate conventional markers of mast cell disease burden (percentage of bone ma …
Multilineage KIT involvement and multimutated clones are characteristic of advanced SM (advSM), especially SM with an associated hematolo …
The international consensus classification of mastocytosis and related entities.
Leguit RJ, Wang SA, George TI, Tzankov A, Orazi A. Leguit RJ, et al. Virchows Arch. 2023 Jan;482(1):99-112. doi: 10.1007/s00428-022-03423-3. Epub 2022 Oct 10. Virchows Arch. 2023. PMID: 36214901 Review.
This includes indolent forms such as indolent systemic mastocytosis and its subvariant bone marrow mastocytosis, and smoldering systemic mastocytosis as well as aggressive forms including aggressive systemic mastocytosis, systemic mastocytosis with an associated myeloid neoplasm …
This includes indolent forms such as indolent systemic mastocytosis and its subvariant bone marrow mastocytosis, and smoldering systemic mas …
New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy.
Valent P, Akin C, Sperr WR, Horny HP, Arock M, Metcalfe DD, Galli SJ. Valent P, et al. Annu Rev Pathol. 2023 Jan 24;18:361-386. doi: 10.1146/annurev-pathmechdis-031521-042618. Epub 2022 Oct 21. Annu Rev Pathol. 2023. PMID: 36270293 Free article. Review.
On the basis of histopathological and molecular features, clinical variables, and organ involvement, SM is divided into indolent SM, smoldering SM, SM with an associated hematologic neoplasm, aggressive SM, and MC leukemia. Each variant is defined by unique diagnost …
On the basis of histopathological and molecular features, clinical variables, and organ involvement, SM is divided into indolent SM, smolder …
Avapritinib for Systemic Mastocytosis.
Bose P, Verstovsek S. Bose P, et al. Expert Rev Hematol. 2021 Aug;14(8):687-696. doi: 10.1080/17474086.2021.1959315. Epub 2021 Aug 6. Expert Rev Hematol. 2021. PMID: 34289787
The vast majority of cases are indolent, with near-normal life expectancy, although symptoms can be severe. AdvSM, comprising aggressive SM, SM with an associated hematologic neoplasm and mast cell leukemia, however, carries a poor prognosis. ...
The vast majority of cases are indolent, with near-normal life expectancy, although symptoms can be severe. AdvSM, comprising aggressive SM, …
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.
Valent P, Hartmann K, Schwaab J, Alvarez-Twose I, Brockow K, Bonadonna P, Hermine O, Niedoszytko M, Carter MC, Hoermann G, Sperr WR, Butterfield JH, Ustun C, Zanotti R, Radia DH, Castells M, Triggiani M, Schwartz LB, Orfao A, George TI, Sotlar K, Gotlib J, Reiter A, Horny HP, Arock M, Akin C, Metcalfe DD. Valent P, et al. J Allergy Clin Immunol Pract. 2022 Aug;10(8):1999-2012.e6. doi: 10.1016/j.jaip.2022.03.007. Epub 2022 Mar 25. J Allergy Clin Immunol Pract. 2022. PMID: 35342031 Free article. Review.
In those with advanced SM, multiple somatic mutations and an associated hematologic neoplasm may be detected. Mediator-related symptoms can occur in any type of mastocytosis. ...
In those with advanced SM, multiple somatic mutations and an associated hematologic neoplasm may be detected. Mediator-related …
Relevant updates in systemic mastocytosis.
Coltoff A, Mascarenhas J. Coltoff A, et al. Leuk Res. 2019 Jun;81:10-18. doi: 10.1016/j.leukres.2019.04.001. Epub 2019 Apr 4. Leuk Res. 2019. PMID: 30978435 Review.
The subtypes of SM include indolent SM (ISM), smoldering SM (SSM), aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL) and survival can range from normal in the case of ISM to months in MCL. ...
The subtypes of SM include indolent SM (ISM), smoldering SM (SSM), aggressive SM (ASM), SM with associated hematologic neoplasm …
ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms.
Sullivan MJ, Palmer EL, Botero JP. Sullivan MJ, et al. Curr Hematol Malig Rep. 2022 Oct;17(5):105-112. doi: 10.1007/s11899-022-00666-4. Epub 2022 Jun 25. Curr Hematol Malig Rep. 2022. PMID: 35751752 Review.
RECENT FINDINGS: ANKRD26-related thrombocytopenia (ANKRD26-RT) is a non-syndromic autosomal dominant thrombocytopenia with predisposition to hematologic neoplasm. The clinical presentation is variable with moderate thrombocytopenia with normal platelet size and abse …
RECENT FINDINGS: ANKRD26-related thrombocytopenia (ANKRD26-RT) is a non-syndromic autosomal dominant thrombocytopenia with predisposition to …
Update on diagnostic approaches and therapeutic strategies in systemic mastocytosis.
Radia DH, Moonim MT. Radia DH, et al. Best Pract Res Clin Haematol. 2022 Jun;35(2):101380. doi: 10.1016/j.beha.2022.101380. Epub 2022 Sep 14. Best Pract Res Clin Haematol. 2022. PMID: 36333068 Review.
This may be due to increases in mast cell burden (leukemic, associated with tumour masses) or more commonly due to the presence of an additional hematologic neoplasm (SM-AHN). These patients with advanced systemic mastocytosis have poor outcome; however, recent adva …
This may be due to increases in mast cell burden (leukemic, associated with tumour masses) or more commonly due to the presence of an additi …
The new tool "KIT" in advanced systemic mastocytosis.
Shomali W, Gotlib J. Shomali W, et al. Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):127-136. doi: 10.1182/asheducation-2018.1.127. Hematology Am Soc Hematol Educ Program. 2018. PMID: 30504301 Free PMC article. Review.
Although mediator symptoms related to mast cell activation can impose a symptom burden in cutaneous disease and across the spectrum of systemic mastocytosis subtypes, the presence of an associated hematologic neoplasm and/or organ damage denotes advanced disease and …
Although mediator symptoms related to mast cell activation can impose a symptom burden in cutaneous disease and across the spectrum of syste …
Hematologic malignancies of the liver: spectrum of disease.
Tomasian A, Sandrasegaran K, Elsayes KM, Shanbhogue A, Shaaban A, Menias CO. Tomasian A, et al. Radiographics. 2015 Jan-Feb;35(1):71-86. doi: 10.1148/rg.351130008. Radiographics. 2015. PMID: 25590389 Review.
Although the imaging features of more common hepatic diseases such as hepatocellular carcinoma, metastases, and infection may overlap with those of hepatic hematologic malignancies, combining the imaging features with clinical manifestations and laboratory findings can facilitate …
Although the imaging features of more common hepatic diseases such as hepatocellular carcinoma, metastases, and infection may overlap with t …
86 results